Cardioprotection on Chemotherapy-Induced Cardiotoxicity

The Effect of Cardioprotective Medications on Chemotherapy-Induced Cardiotoxicity in Childhood Acute Leukemia

The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.

The goal of this interventional study is to evaluate the protective impact of Angiotensin-converting enzyme (ACE) inhibitors versus β-blockers on the cardiotoxicity profile of pediatric patients with acute leukemia. The impact is measured by evaluation of left ventricular ejection fraction (LVEF) by 2D echocardiography at baseline and at the end of Induction phase (42 days).

Inclusion Criteria:

• Willingness of the legal representative of research participant to participate in the study by giving "informed consent."
• Ability to take oral medication.
• Age 2-18 years at the time of diagnosis.

Exclusion Criteria:

• Documented allergy to cardioprotective medications